| Abstract: |
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. |
| Inventor: |
Ciaramella, Giuseppe (Sudbury, MA, US); Himansu, Sunny (Winchester, MA, US) |
| Applicant: |
ModernaTX, Inc. (Cambridge, MA, US) |
| Face Assignee: |
ModernaTX, Inc. (Cambridge, MA, US) |
| Filed: |
2020-05-21 |
| Issued: |
2020-09-10 |
| Claims: |
24 |
|
US20200282046
|
136. A method comprising administering to a subject a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a Betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle in an effective amount to induce in the subject an immune response to the Betacoronavirus S protein or S protein subunit.
(8)
(0)
|
|
154. A method comprising administering to a subject an mRNA comprising a 5′ cap analog, a 5′ untranslated region, an open reading frame encoding a BetaCoV S protein or S protein subunit, a 3′ untranslated region, and a poly(A) tail formulated in a lipid nanoparticle in an effective amount to induce in the subject an immune response to the BetaCoV S protein or S protein subunit, wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid.
(1)
(0)
|
|
